Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × Gastrointestinal Stromal Tumors × IDRX-42 × Clear all

Phase

Phase 3 1 Phase 1 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1 Gastrointestinal 1

Conditions

Gastrointestinal Stromal Tumors 1 Gastrointestinal Neoplasms 1

Interventions

Imatinib Mesylate 17 Sunitinib 8 nilotinib 4 ripretinib 3 masitinib 2 tanespimycin 1 regorafenib 1 famitinib 1 Sodium Chloride 1 Immunoglobulin G 1 IDRX-42 1 Fentanyl 1 Disulfides 1 Carnitine 1 Bevacizumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT07218926 2026-01-30

A Study of IDRX-42 (GSK6042981) Versus (vs) Sunitinib in Participants With Gastrointestinal Stromal Tumors After Imatinib Therapy

GlaxoSmithKline

Phase 3 Recruiting

GastrointestinalSarcoma

Gastrointestinal Neoplasms, Gastrointestinal Stromal Tumors

Data powered by HemOnc (CC BY 4.0) Colophon ⚡